FDA grants supplemental approval for PRECEDEX (dexmedetomidine hydrochloride)
The FDA has granted supplemental approval for PRECEDEX, a sedative agent, under NDA021038.
Published: August 2, 2026
Updated: August 2, 2026
Author: Humanexa Intelligence
Therapeutic area: Anesthesia / Sedative
Asset: Hospira
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Hospira
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's supplemental approval for PRECEDEX is significant as it may enhance Hospira's competitive position in the anesthesia sector. This approval opens opportunities for expanded clinical use, which could lead to increased market share and revenue.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for further details on the indications and market uptake of PRECEDEX following this approval.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.